Journal Article Summary
The article investigates the use of doxepin, a medication not currently approved for pediatric insomnia by the FDA, in treating sleep difficulties among children and adolescents, particularly those with neurodevelopmental disorders. Insomnia is a common issue in this age group, and finding effective treatments is crucial, especially when standard therapies like behavioral interventions and melatonin do not work. Understanding how doxepin performs in this context could provide valuable insights for managing pediatric insomnia.
The study involved a review of medical records from 29 children and adolescents aged 2 to 17 years who had not responded to initial treatments for insomnia. Doxepin was administered starting at a low dose of 2 mg, which was gradually increased to a maintenance dose of 10 mg. After an average follow-up period of about 6.5 months, the results indicated that 27.6% of the participants experienced significant improvement in their sleep, while another 27.6% showed moderate improvement. Only a small number of patients discontinued the medication due to side effects or lack of effectiveness, and a few experienced behavioral issues or bedwetting.
Despite the promising results, the study has limitations, including its small sample size and retrospective design, which may affect the reliability of the findings. Patients and caregivers should be cautious and consult healthcare professionals before considering doxepin for insomnia, especially since it is not FDA-approved for this use in children. Discussing potential benefits and risks with a doctor can help ensure safe and effective treatment options for managing insomnia in pediatric patients.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Shah Yash D., Stringel Virginia, Pavkovic Ivan, Kothare Sanjeev V.. Doxepin in children and adolescents with symptoms of insomnia: a single-center experience. Journal of Clinical Sleep Medicine : JCSM : Official Publication of the American Academy of Sleep Medicine 2020. DOI: 10.5664/jcsm.8338. PMID: 32029069. PMCID: PMC7849801.
Featured Pill Pals Product
Doxepin 10 mg Capsules --- Generic For Sinequan --- Alembic
Doxepin 10 mg Capsules — Generic For Sinequan — Alembic is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. Prescription required.
Request a prescription transfer and our pharmacy team will help coordinate the next step.
